

# Roberto Ceravolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7857249/publications.pdf>

Version: 2024-02-01

245  
papers

9,209  
citations

47006

47  
h-index

58581

82  
g-index

250  
all docs

250  
docs citations

250  
times ranked

9857  
citing authors

#	ARTICLE	IF	CITATIONS
1	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	3.9	1,171
2	The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. <i>Annals of Neurology</i> , 1999, 45, 577-582.	5.3	306
3	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. <i>Annals of Neurology</i> , 2000, 48, 689-695.	5.3	246
4	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.	3.6	188
5	Psychiatric comorbidity in a population of Parkinson's disease patients. <i>European Journal of Neurology</i> , 2004, 11, 315-320.	3.3	173
6	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	3.6	140
7	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	3.9	139
8	Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 601-606.	1.9	130
9	Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. <i>Neurology</i> , 2000, 55, 1216-1218.	1.1	124
10	Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study. <i>Movement Disorders</i> , 2013, 28, 1391-1397.	3.9	114
11	MR Imaging of the Substantia Nigra at 7 T Enables Diagnosis of Parkinson Disease. <i>Radiology</i> , 2014, 271, 831-838.	7.3	114
12	Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study. <i>Scientific Reports</i> , 2017, 7, 39471.	3.3	108
13	Progression of tremor in early stages of Parkinson's disease: a clinical and neuroimaging study. <i>Brain</i> , 2018, 141, 811-821.	7.6	107
14	Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S111-S115.	2.2	101
15	<sup>18</sup> F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. <i>Synapse</i> , 2002, 43, 201-207.	1.2	100
16	Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: Focus on sleep and cognitive domains. <i>Journal of the Neurological Sciences</i> , 2010, 289, 44-48.	0.6	99
17	A molecular signature in blood identifies early Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2012, 7, 26.	10.8	99
18	Prevalence of fatigue in Parkinson disease and its clinical correlates. <i>Neurology</i> , 2014, 83, 215-220.	1.1	98

#	ARTICLE	IF	CITATIONS
19	SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 221-227.	0.7	97
20	Clozapine in Parkinson's disease tremor. <i>Neurology</i> , 1997, 49, 1587-1590.	1.1	94
21	Orthostatic Hypotension in De Novo Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 1400.	4.5	93
22	Relationship Between Left Ventricular Mass and Endothelium-Dependent Vasodilation in Never-Treated Hypertensive Patients. <i>Circulation</i> , 1999, 99, 1991-1996.	1.6	90
23	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017, 32, 181-192.	3.9	88
24	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011, 6, e18301.	2.5	84
25	Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 37-42.	2.1	82
26	Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2015, 36, 461-466.	2.4	80
27	A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 691-694.	1.4	79
28	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 528-531.	2.2	77
29	Differences in nigrostriatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. <i>European Journal of Neurology</i> , 2010, 17, 626-630.	3.3	75
30	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in $\alpha$ -synucleinopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1257-1263.	1.9	73
31	From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 65-71.	2.1	72
32	Pisa syndrome in Parkinson disease. <i>Neurology</i> , 2015, 85, 1769-1779.	1.1	72
33	Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. <i>Experimental Neurology</i> , 2003, 182, 421-426.	4.1	70
34	Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region. <i>Journal of Neurology</i> , 2021, 268, 1179-1187.	3.6	70
35	Acute and chronic effects of clozapine in essential tremor. <i>Movement Disorders</i> , 1999, 14, 468-472.	3.9	69
36	Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Endothelium-Dependent Vasodilation in Never Treated Hypertensive Patients. <i>Hypertension</i> , 1998, 31, 900-905.	2.7	66

#	ARTICLE	IF	CITATIONS
37	Association between amantadine and the onset of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1375-1379.	3.9	66
38	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. <i>Brain</i> , 2020, 143, 1780-1797.	7.6	66
39	Molecular Imaging of the Dopamine Transporter. <i>Cells</i> , 2019, 8, 872.	4.1	62
40	The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. <i>Genetic and Molecular Aspects. Current Alzheimer Research</i> , 2009, 6, 224-237.	1.4	58
41	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 775-780.	2.2	58
42	Clozapine in Huntington's chorea. <i>Neurology</i> , 1994, 44, 821-821.	1.1	58
43	Parkinson's Disease and pathological gambling: Results from a functional MRI study. <i>Movement Disorders</i> , 2010, 25, 2449-2453.	3.9	57
44	Decision making in de novo Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1432-1436.	3.9	56
45	Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction. <i>European Journal of Neurology</i> , 2013, 20, 480-485.	3.3	52
46	Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 59-62.	2.2	51
47	Î±-Synuclein Heterocomplexes with Î²-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 53.	2.9	51
48	Cerebral Perfusional Effects of Cholinesterase Inhibitors in Alzheimer Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 166-170.	0.7	50
49	Cerebello-thalamo-cortical network is intrinsically altered in essential tremor: evidence from a resting state functional MRI study. <i>Scientific Reports</i> , 2020, 10, 16661.	3.3	50
50	Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma. <i>Movement Disorders</i> , 2000, 15, 350-352.	3.9	49
51	CSF phosphorylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. <i>Brain Research Bulletin</i> , 2008, 76, 80-84.	3.0	49
52	Quantitative susceptibility mapping in atypical Parkinsonisms. <i>NeuroImage: Clinical</i> , 2019, 24, 101999.	2.7	49
53	Role of Pramipexole in the Management of Parkinson's Disease. <i>CNS Drugs</i> , 2010, 24, 829-841.	5.9	48
54	Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. <i>Movement Disorders</i> , 2012, 27, 1679-1682.	3.9	48

#	ARTICLE	IF	CITATIONS
55	Serotonergic Polymorphisms (<i>5-HTTLPR</i> and <i>5-HT2A</i>): Association Studies with Psychosis in Alzheimer Disease. <i>Genetic Testing and Molecular Biomarkers</i> , 2003, 7, 309-314.	1.7	47
56	Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. <i>Journal of Neural Transmission</i> , 2004, 111, 1065-73.	2.8	45
57	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 522-526.	2.2	45
58	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	1.5	45
59	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	3.3	45
60	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 90-92.	2.2	44
61	Understanding the Multiple Role of Mitochondria in Parkinson's Disease and Related Disorders: Lesson From Genetics and Protein-Protein Interaction Network. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636506.	3.7	44
62	A Systematic Review of Catechol-O-Methyltransferase Inhibitors. <i>Clinical Neuropharmacology</i> , 2012, 35, 185-190.	0.7	43
63	Familial Progressive supranuclear Palsy. <i>Archives of Neurology</i> , 2001, 58, 1846.	4.5	42
64	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	3.1	42
65	Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany. <i>Neurological Sciences</i> , 2007, 28, 142-147.	1.9	41
66	Biologic Features (Inflammation and Neoangiogenesis) and Atherosclerotic Risk Factors in Carotid Plaques and Calcified Aortic Valve Stenosis. <i>American Journal of Clinical Pathology</i> , 2006, 126, 494-502.	0.7	39
67	Deep Brain Stimulation of Pedunculopontine Tegmental Nucleus (PPTg) Promotes Cognitive and Metabolic Changes: A Target-Specific Effect or Response to a Low-Frequency Pattern of Stimulation?. <i>Clinical EEG and Neuroscience</i> , 2010, 41, 82-86.	1.7	39
68	Movement disorders: role of imaging in diagnosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 239-256.	3.4	39
69	Morphometric and functional MRI changes in essential tremor with and without resting tremor. <i>Journal of Neurology</i> , 2015, 262, 719-728.	3.6	39
70	Midbrain MRI assessments in progressive supranuclear palsy subtypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 98-103.	1.9	39
71	Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: a systematic review of current literature. <i>Journal of Neurology</i> , 2021, 268, 1561-1569.	3.6	39
72	Comparison of endothelial function evaluated by strain gauge plethysmography and brachial artery ultrasound. <i>Atherosclerosis</i> , 2001, 158, 53-59.	0.8	38

#	ARTICLE	IF	CITATIONS
73	Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. <i>Journal of Neurology</i> , 2010, 257, 276-283.	3.6	38
74	Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. <i>Schizophrenia Research</i> , 2014, 152, 344-349.	2.0	38
75	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020, 35, 976-983.	3.9	38
76	Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. <i>Neurological Sciences</i> , 2003, 24, 162-163.	1.9	36
77	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> , 2005, 65, 1971-1973.	1.1	36
78	Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 576-585.	1.5	36
79	Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 685-687.	1.9	35
80	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. <i>Movement Disorders</i> , 2008, 23, 2049-2054.	3.9	35
81	The Italian Dystonia Registry: rationale, design and preliminary findings. <i>Neurological Sciences</i> , 2017, 38, 819-825.	1.9	35
82	Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art. <i>Neuroscience Letters</i> , 2013, 556, 1-4.	2.1	34
83	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 557-559.	2.2	33
84	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	4.0	33
85	Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study. <i>Movement Disorders</i> , 2007, 22, 2170-2175.	3.9	32
86	Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients. <i>European Journal of Neurology</i> , 2011, 18, 842-849.	3.3	32
87	[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. <i>Schizophrenia Research</i> , 2012, 139, 40-45.	2.0	32
88	Factors influencing psychological well-being in patients with Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0189682.	2.5	32
89	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2012, 3, 159.	2.4	31
90	Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 671-672.	2.2	31

#	ARTICLE	IF	CITATIONS
91	No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 371-378.	2.6	30
92	Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. <i>Neuroscience Letters</i> , 2007, 422, 228-231.	2.1	30
93	Decreased and increased cortical activation coexist in de novo Parkinson's disease. <i>Experimental Neurology</i> , 2010, 224, 299-306.	4.1	30
94	The association between motor subtypes and alexithymia in de novo Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1042-1045.	3.6	30
95	Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 761-765.	2.2	30
96	A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 181-198.	2.4	30
97	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	2.4	30
98	Impact of Coronavirus Disease 2019 Pandemic on Cognition in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1717-1718.	3.9	30
99	Adherence to anti-Parkinson drug therapy in the REASON-sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the Morisky Medical Adherence scale-8 items. <i>Neurological Sciences</i> , 2013, 34, 2015-2022.	1.9	29
100	Alexithymia Is Associated with Depression in de novo Parkinson's Disease. <i>Psychotherapy and Psychosomatics</i> , 2011, 80, 251-253.	8.8	28
101	The hOGG1 Ser326Cys polymorphism and Huntington's disease. <i>Toxicology</i> , 2010, 278, 199-203.	4.2	27
102	Antipsychotic drugs in Huntington's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 227-237.	2.8	27
103	The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 124-131.	1.3	26
104	Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 191-195.	2.1	26
105	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. <i>Journal of Neurology</i> , 2020, 267, 2949-2960.	3.6	26
106	Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 481-485.	2.2	25
107	Parkinson-dementia diseases: A comparison by double tracer SPECT studies. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 762-766.	2.2	25
108	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2269-2280.	1.8	25

#	ARTICLE	IF	CITATIONS
109	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.1	25
110	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021, 268, 4737-4743.	3.6	25
111	Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 81-84.	2.2	24
112	Potential Diagnostic Value of Red Blood Cells $\alpha$ -Synuclein Heteroaggregates in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 6451-6459.	4.0	24
113	Reliability of administrative data for the identification of Parkinson's disease cohorts. <i>Neurological Sciences</i> , 2015, 36, 783-786.	1.9	23
114	Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation. <i>Journal of Neural Transmission</i> , 2015, 122, 1143-1147.	2.8	23
115	Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 105-109.	2.2	23
116	Implantation of the nucleus tegmenti pedunculo pontini in a PSP patient: Safe procedure, modest benefits. <i>Movement Disorders</i> , 2009, 24, 2020-2022.	3.9	22
117	Gait dynamics in Pisa syndrome and Camptocormia: The role of stride length and hip kinematics. <i>Gait and Posture</i> , 2017, 57, 130-135.	1.4	22
118	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. <i>Journal of Neural Transmission</i> , 2020, 127, 1435-1439.	2.8	22
119	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021, 36, 681-689.	3.9	22
120	Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus. <i>Movement Disorders</i> , 2021, 36, 124-132.	3.9	22
121	Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. <i>European Journal of Neurology</i> , 2003, 10, 461-462.	3.3	21
122	Apomorphine hydrochloride for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 723-732.	2.8	21
123	Effect of type D personality on smoking status and their combined impact on outcome after acute myocardial infarction. <i>Clinical Cardiology</i> , 2018, 41, 321-325.	1.8	21
124	Idiopathic <sc>Non-task-specific</sc> Upper Limb Dystonia, a Neglected Form of Dystonia. <i>Movement Disorders</i> , 2020, 35, 2038-2045.	3.9	21
125	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 6-19.	1.5	21
126	Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. <i>Journal of Neural Transmission</i> , 2006, 113, 1787-1790.	2.8	20



#	ARTICLE	IF	CITATIONS
127	Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 159-165.	2.2	20
128	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. <i>Journal of Personalized Medicine</i> , 2020, 10, 221.	2.5	20
129	Neuroimaging in Parkinson's disease: focus on substantia nigra and nigro-striatal projection. <i>Current Opinion in Neurology</i> , 2017, 30, 416-426.	3.6	19
130	Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11234.	4.1	19
131	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	1.9	18
132	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. <i>Movement Disorders</i> , 2015, 30, 1148-1149.	3.9	18
133	Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease. <i>PLoS ONE</i> , 2015, 10, e0125259.	2.5	18
134	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 40-43.	2.2	18
135	Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus. <i>Neurology</i> , 2021, 96, e2861-e2873.	1.1	18
136	The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 473, 248-251.	2.1	17
137	Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study. <i>Movement Disorders</i> , 2020, 35, 1028-1036.	3.9	17
138	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between $\alpha$ -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	3.6	17
139	Development and Validation of Automated $\alpha$ -Synuclein Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy from Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1272-1281.	3.9	17
140	Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1130-1135.	2.2	16
141	Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. <i>Journal of Neural Transmission</i> , 2016, 123, 509-513.	2.8	16
142	A single center study: $A\beta_{42}/p\text{-Tau181}$ CSF ratio to discriminate AD from FTD in clinical setting. <i>Neurological Sciences</i> , 2017, 38, 1791-1797.	1.9	16
143	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020, 17, 543-559.	3.0	16
144	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 448-454.	3.6	16

#	ARTICLE	IF	CITATIONS
145	Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 35-41.	1.9	15
146	Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2020, 11, 207.	2.4	15
147	Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms. <i>Archives Italiennes De Biologie</i> , 2018, 156, 27-39.	0.4	15
148	Diagnosis, assessment and management of delusional jealousy in Parkinson's disease with and without dementia. <i>Neurological Sciences</i> , 2013, 34, 1537-1541.	1.9	14
149	Cognitive disorders in normal pressure hydrocephalus with initial parkinsonism in comparison with de novo Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 74-79.	3.3	14
150	Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinson's Disease Patients. <i>Genes</i> , 2021, 12, 720.	2.4	14
151	Current treatment and future prospects of dopa-induced dyskinesias. <i>Drugs of Today</i> , 2015, 51, 315.	1.1	14
152	The mtDNA A8344G $\alpha$ -MERRF mutation is not a common cause of sporadic Parkinson disease in Italian population. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 381-382.	2.2	13
153	Nigral involvement and nigrostriatal dysfunction in Huntington's disease: Evidences from an MRI and SPECT study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 800-805.	2.2	13
154	The Precuneus – A Witness for Excessive A $\beta$ 2 Gathering in Alzheimer's Disease Pathology. <i>Neurodegenerative Diseases</i> , 2018, 18, 302-309.	1.4	13
155	Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 597-609.	2.6	13
156	Extended release levodopa at bedtime as a treatment for nocturia in Parkinson's disease: An open label study. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116625.	0.6	13
157	Lumboperitoneal shunt in idiopathic normal pressure hydrocephalus: a prospective controlled study. <i>Journal of Neurology</i> , 2020, 267, 2556-2566.	3.6	13
158	Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. <i>Frontiers in Neurology</i> , 2021, 12, 798191.	2.4	13
159	Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 1158-1162.	1.8	12
160	Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault?. <i>Journal of the Neurological Sciences</i> , 2016, 366, 167-170.	0.6	12
161	P2X7 receptor/NLRP3 inflammasome complex and $\alpha$ -synuclein in peripheral blood mononuclear cells: a prospective study in newly diagnosed, treatment-naïve Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 2648-2656.	3.3	12
162	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018, 1750, 139-155.	0.9	12

#	ARTICLE	IF	CITATIONS
163	Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. <i>Neuroscience Letters</i> , 2008, 444, 83-86.	2.1	11
164	Bilateral thalamic glioma presenting with parkinsonism. <i>Movement Disorders</i> , 2009, 24, 2168-2169.	3.9	11
165	Social Cognition and Oxytocin in Huntington's Disease: New Insights. <i>Brain Sciences</i> , 2018, 8, 161.	2.3	11
166	Non-pharmacological interventions for Parkinson's disease mild cognitive impairment: future directions for research. <i>Neural Regeneration Research</i> , 2020, 15, 1650.	3.0	11
167	Limbic encephalitis associated with thymic cancer: a case report. <i>Journal of Neurology</i> , 2001, 248, 1000-1002.	3.6	10
168	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. <i>Future Neurology</i> , 2010, 5, 851-871.	0.5	10
169	Expanding the clinical phenotype of <i>DYT5</i> mutations: Is multiple system atrophy a possible one?. <i>Neurology</i> , 2013, 81, 301-302.	1.1	10
170	Symptomatic orthostatic tremor associated with Graves' disease. <i>Neurological Sciences</i> , 2014, 35, 929-931.	1.9	10
171	Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients. <i>Clinical Neuropharmacology</i> , 2017, 40, 34-36.	0.7	10
172	Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 31.	4.2	10
173	Adult-onset mitochondrial movement disorders: a national picture from the Italian Network. <i>Journal of Neurology</i> , 2022, 269, 1413-1421.	3.6	10
174	Myopathic involvement in two cases of Hallervorden-Spatz disease. <i>Brain and Development</i> , 1995, 17, 286-290.	1.1	9
175	The safety of dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 111-127.	2.4	9
176	Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. <i>Movement Disorders</i> , 2012, 27, 1706-1706.	3.9	9
177	Depressive symptoms in Parkinson's disease. <i>Comprehensive Psychiatry</i> , 2012, 53, 727-731.	3.1	9
178	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1643-1653.	1.8	9
179	Pisa syndrome in Idiopathic Normal Pressure Hydrocephalus. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 40-44.	2.2	9
180	$\alpha$ -Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 885-893.	2.6	9

#	ARTICLE	IF	CITATIONS
181	Alexithymia may modulate decision making in patients with de novo Parkinson's disease. <i>Functional Neurology</i> , 2011, 26, 127-31.	1.3	9
182	Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5393.	4.1	9
183	Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 279-283.	2.2	8
184	Freezing of gait and dementia in parkinsonism: A retrospective case-control study. <i>Brain and Behavior</i> , 2019, 9, e01247.	2.2	8
185	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	3.0	8
186	Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2302.	2.4	8
187	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 70-74.	2.2	8
188	Statins in Parkinson's Disease: Influence on Motor Progression. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1651-1662.	2.8	8
189	Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies. <i>NeuroImage</i> , 2022, 260, 119454.	4.2	8
190	Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo. , 2006, , 133-141.		7
191	Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers. <i>Movement Disorders</i> , 2012, 27, 330-332.	3.9	6
192	Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. <i>Neurological Sciences</i> , 2015, 36, 935-943.	1.9	6
193	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E129-39.	1.7	6
194	Efficacy of a combined therapeutic approach in the management of Pisa Syndrome. <i>NeuroRehabilitation</i> , 2017, 41, 249-253.	1.3	6
195	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. <i>Frontiers in Neurology</i> , 2020, 11, 906.	2.4	6
196	Bipolar Spectrum disorders in Parkinson's disease: a systematic evaluation. <i>CNS Spectrums</i> , 2022, 27, 355-361.	1.2	6
197	Aerobic rehabilitation program for improving muscle function in Parkinson's disease. <i>Restorative Neurology and Neuroscience</i> , 2018, 36, 13-20.	0.7	5
198	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019, 40, 2587-2594.	1.9	5

#	ARTICLE	IF	CITATIONS
199	Validation of the Italian version of carersâ€™ quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq1 1 0.784314 rgBT <sub>5</sub> /Overlo	1.9	5
200	Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. Brain and Behavior, 2019, 9, e01182.	2.2	5
201	Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration?. Neurological Sciences, 2021, 42, 723-726.	1.9	5
202	Positive DAT-SCAN in SPG7: a case report mimicking possible MSA-C. BMC Neurology, 2021, 21, 328.	1.8	5
203	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. Movement Disorders Clinical Practice, 2021, 8, 1107-1111.	1.5	5
204	A case of pelvic floor myoclonic jerk syndrome. Movement Disorders, 1996, 11, 331-333.	3.9	4
205	Mitochondrial DNA single deletion in a patient with postural tremor. Movement Disorders, 2008, 23, 2098-2100.	3.9	4
206	Unilateral periodic limb movements: Is this a pointer for atypical presentation of corticobasal degeneration syndrome?â€™ A case report. Movement Disorders, 2009, 24, 2298-2299.	3.9	4
207	A pilot psychometric study of aberrant salience state in patients with Parkinsonâ€™s disease and its association with dopamine replacement therapy. Neurological Sciences, 2014, 35, 1603-1605.	1.9	4
208	Leadless cardiac pacemaker implant in a patient with two deep brain stimulators: A peaceful cohabitation beyond prejudices. International Journal of Cardiology, 2016, 223, 136-138.	1.7	4
209	Arterial stiffness and mitral regurgitation in arterial hypertension: an intriguing pathophysiological link. Vascular Pharmacology, 2018, 111, 71-76.	2.1	4
210	Theory of mind in Parkinsonâ€™s disease: evidences in drug-naïve patients and longitudinal effects of dopaminergic therapy. Neurological Sciences, 2020, 41, 2761-2766.	1.9	4
211	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimerâ€™s and other neurodegenerative diseases. Expert Review of Neurotherapeutics, 2021, 21, 949-967.	2.8	4
212	Functional gait disorders: Demographic and clinical correlations. Parkinsonism and Related Disorders, 2021, 91, 32-36.	2.2	4
213	Fluid Biomarkers in Alzheimerâ€™s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics, 2022, 12, 796.	2.6	4
214	Dysphagia in Parkinson's disease: Pharyngeal manometry and fiberoptic endoscopic evaluation. Auris Nasus Larynx, 2022, 49, 986-994.	1.2	4
215	Î±-synuclein as an emerging pathophysiological biomarker of Alzheimerâ€™s disease. Expert Review of Molecular Diagnostics, 2022, 22, 411-425.	3.1	4
216	Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms. European Journal of Neurology, 2022, 29, 2944-2955.	3.3	4

#	ARTICLE	IF	CITATIONS
217	Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. <i>Neurodegenerative Diseases</i> , 2015, 15, 271-280.	1.4	3
218	Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis. <i>Neurological Sciences</i> , 2021, 42, 1483-1490.	1.9	3
219	Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinson's disease?. <i>Neurological Sciences</i> , 2022, 43, 3641-3647.	1.9	3
220	Doctor "how quickly will my Parkinson's progress?. <i>European Journal of Neurology</i> , 2015, 22, 421-422.	3.3	2
221	Confabulations in Cases of Dementia: Atypical Early Sign of Alzheimer's Disease or Misleading Feature in Dementia Diagnosis?. <i>Frontiers in Psychology</i> , 2020, 11, 553886.	2.1	2
222	Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. <i>Frontiers in Psychology</i> , 2021, 12, 546476.	2.1	2
223	Tardive Syndrome Associated With Tetrabenazine in Huntington Disease. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 628-630.	1.4	2
224	The Molecular Neuroimaging of Tremor. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 74.	4.2	2
225	Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 32-39.	2.1	1
226	P1.091 Parkinson's disease and pathological gambling: results from a fMRI study investigating cue induced brain activity. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S52.	2.2	1
227	MR Imaging of the Substantia Nigra for the Diagnosis of Parkinson Disease. <i>Radiology</i> , 2014, 273, 627-628.	7.3	1
228	Dopamine Agonist Modifies Cortical Activity in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2014, 37, 166-172.	0.7	1
229	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021, 36, 2703-2705.	3.9	1
230	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 757-766.	2.6	1
231	Negative DAT-SPECT in Old Onset Parkinson's Disease: An Additional Pitfall?. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 530-534.	1.5	1
232	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 266-267.	2.2	0
233	Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E26-E26.	1.8	0
234	Movement disorders: role of imaging in diagnosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, spcone-spcone.	3.4	0

#	ARTICLE	IF	CITATIONS
235	Cataract Surgery under Topical Anesthesia in a Patient with Parkinson Disease and Deep Brain Stimulation: A Report of Feasibility. <i>European Journal of Ophthalmology</i> , 2015, 25, 258-259.	1.3	0
236	Head tremor as a warning symptom of rapidly progressive syringomyelia: a case report. <i>Neurological Sciences</i> , 2018, 39, 1497-1499.	1.9	0
237	OC.05.3 HISTOMORPHOLOGICAL AND MOLECULAR CHARACTERIZATION OF PARKINSON'S DISEASE PATIENTS WITH CONSTIPATION: A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e89.	0.9	0
238	Red blood cell $\alpha$ -synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the AD-LBD spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e040618.	0.8	0
239	Sex differences in red blood cell $\alpha$ -synuclein protein and its heteroaggregates with amyloid $\beta$ and tau in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042079.	0.8	0
240	Assessment of the integrity of the noradrenergic nucleus locus coeruleus during normal ageing by neuromelanin-MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e043332.	0.8	0
241	In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimer's disease and other types of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e043616.	0.8	0
242	Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy". <i>Movement Disorders</i> , 2021, 36, 2208-2209.	3.9	0
243	Early Compensatory Mechanisms in <i>LRRK2</i> Mutation Carriers. <i>Movement Disorders</i> , 2022, 37, 662-663.	3.9	0
244	Biological Features (Inflammation and Neoangiogenesis) and Atherosclerotic Risk Factors in Carotid Plaques and Calcified Aortic Valve Stenosis: Two Different Sites of the Same Disease?. <i>American Journal of Clinical Pathology</i> , 2006, 126, 494-502.	0.7	0
245	Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E26-E26.	1.8	0